AU530999B2 - Substituted amino triazines and their use in treatment of cns disorders - Google Patents

Substituted amino triazines and their use in treatment of cns disorders

Info

Publication number
AU530999B2
AU530999B2 AU58906/80A AU5890680A AU530999B2 AU 530999 B2 AU530999 B2 AU 530999B2 AU 58906/80 A AU58906/80 A AU 58906/80A AU 5890680 A AU5890680 A AU 5890680A AU 530999 B2 AU530999 B2 AU 530999B2
Authority
AU
Australia
Prior art keywords
treatment
substituted amino
cns disorders
amino triazines
triazines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired, expires
Application number
AU58906/80A
Other languages
English (en)
Other versions
AU5890680A (en
Inventor
Martin George Baxter
Albert Reginald Elphick
Alistair Ainslie Miller
David Alan Sawyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10505597&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU530999(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of AU5890680A publication Critical patent/AU5890680A/en
Application granted granted Critical
Publication of AU530999B2 publication Critical patent/AU530999B2/en
Adjusted expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16—Compounds containing any of the groups, e.g. aminoguanidine
    • C07C281/18—Compounds containing any of the groups, e.g. aminoguanidine the other nitrogen atom being further doubly-bound to a carbon atom, e.g. guanylhydrazones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/15—Preparation of carboxylic acids or their salts, halides or anhydrides by reaction of organic compounds with carbon dioxide, e.g. Kolbe-Schmitt synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
    • C07C51/363—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU58906/80A 1979-06-01 1980-05-30 Substituted amino triazines and their use in treatment of cns disorders Expired AU530999B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB7919257 1979-06-01
GB7919257 1979-06-01

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU14051/83A Division AU566870B2 (en) 1979-06-01 1983-04-28 Aminoguanidine derivative of substituted benzoyl cyanide

Publications (2)

Publication Number Publication Date
AU5890680A AU5890680A (en) 1980-12-04
AU530999B2 true AU530999B2 (en) 1983-08-04

Family

ID=10505597

Family Applications (2)

Application Number Title Priority Date Filing Date
AU58906/80A Expired AU530999B2 (en) 1979-06-01 1980-05-30 Substituted amino triazines and their use in treatment of cns disorders
AU14051/83A Expired AU566870B2 (en) 1979-06-01 1983-04-28 Aminoguanidine derivative of substituted benzoyl cyanide

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU14051/83A Expired AU566870B2 (en) 1979-06-01 1983-04-28 Aminoguanidine derivative of substituted benzoyl cyanide

Country Status (30)

Country Link
US (2) US4486354A (cg-RX-API-DMAC10.html)
EP (2) EP0021121B1 (cg-RX-API-DMAC10.html)
JP (2) JPS5625169A (cg-RX-API-DMAC10.html)
AR (1) AR227521A1 (cg-RX-API-DMAC10.html)
AT (1) AT370097B (cg-RX-API-DMAC10.html)
AU (2) AU530999B2 (cg-RX-API-DMAC10.html)
BG (1) BG60427B2 (cg-RX-API-DMAC10.html)
CA (1) CA1112643A (cg-RX-API-DMAC10.html)
CS (1) CS234018B2 (cg-RX-API-DMAC10.html)
CZ (1) CZ384891A3 (cg-RX-API-DMAC10.html)
DD (1) DD151309A5 (cg-RX-API-DMAC10.html)
DK (1) DK153787C (cg-RX-API-DMAC10.html)
ES (1) ES491998A0 (cg-RX-API-DMAC10.html)
FI (1) FI67844C (cg-RX-API-DMAC10.html)
GE (1) GEP19960470B (cg-RX-API-DMAC10.html)
GR (1) GR68380B (cg-RX-API-DMAC10.html)
HU (1) HU182086B (cg-RX-API-DMAC10.html)
IE (1) IE49823B1 (cg-RX-API-DMAC10.html)
IL (1) IL60201A (cg-RX-API-DMAC10.html)
IT (1) IT1147087B (cg-RX-API-DMAC10.html)
MX (1) MX9202962A (cg-RX-API-DMAC10.html)
MY (1) MY8500062A (cg-RX-API-DMAC10.html)
NL (1) NL950007I2 (cg-RX-API-DMAC10.html)
NZ (1) NZ193890A (cg-RX-API-DMAC10.html)
PL (1) PL124029B1 (cg-RX-API-DMAC10.html)
SU (1) SU1055331A3 (cg-RX-API-DMAC10.html)
UA (1) UA5576A1 (cg-RX-API-DMAC10.html)
YU (1) YU145680A (cg-RX-API-DMAC10.html)
ZA (1) ZA803250B (cg-RX-API-DMAC10.html)
ZW (1) ZW12980A1 (cg-RX-API-DMAC10.html)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0024351B1 (en) * 1979-08-16 1984-10-31 The Wellcome Foundation Limited Solid pharmaceutical formulation containing substitued phenyl-triazines
GB8328757D0 (en) * 1983-10-27 1983-11-30 Wellcome Found Chemical compounds
DE3600891A1 (de) * 1986-01-15 1987-07-16 Bayer Ag 1,8-verbrueckte 4-chinolon-3-carbonsaeuren und diese enthaltende arzneimittel
GB8613183D0 (en) * 1986-05-30 1986-07-02 Wellcome Found Triazine salt
US4972496A (en) * 1986-07-25 1990-11-20 Grid Systems Corporation Handwritten keyboardless entry computer system
FI895821A7 (fi) 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
US5136080A (en) * 1989-12-04 1992-08-04 Burroughs Wellcome Co. Nitrile compounds
GB9012312D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9012311D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9124807D0 (en) * 1991-11-22 1992-01-15 Wellcome Found Pharmaceutical formulations
US5629016A (en) * 1991-01-30 1997-05-13 Glaxo Wellcome Inc. Water-dispersible tablets
IE77165B1 (en) * 1991-01-30 1997-12-03 Wellcome Found Water-dispersible tablet containing acyclovir
GB9203483D0 (en) * 1992-02-19 1992-04-08 Wellcome Found Anti-inflammatory compounds
DK0644763T3 (da) * 1992-06-12 1997-07-28 Wellcome Found Anvendelse af 3,5-diamino-6-(2,3-dichlorphenyl)-1,2,4-triacin-isethionat til behandlingen og forebyggelsen af afhængighed, tolerance og sensitivering af medikamenter
GB9215908D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
US6133299A (en) * 1993-02-25 2000-10-17 Warner-Lambert Company Methods for treating neurodegenerative diseases and disorders using N-(2,6-disubstituted aromatic)-N'-pyridinyl ureas and other anticonvulsant compounds
US5866597A (en) * 1993-03-19 1999-02-02 Glaxo Wellcome Inc. Use of triazine compounds for the treatment of memory and learning disorders
GB9305693D0 (en) * 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
GB9305692D0 (en) * 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
US5698226A (en) * 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets
GB9317146D0 (en) * 1993-08-18 1993-10-06 Wellcome Found Therapeutic combinations
GB9424766D0 (en) * 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
PT800520E (pt) * 1994-12-30 2002-11-29 Wellcome Found Processo para a preparacao de lamotrigina
GB9426448D0 (en) * 1994-12-30 1995-03-01 Wellcome Found Process
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
GB9518027D0 (en) * 1995-09-05 1995-11-08 Wellcome Found Pharmacologically active compound
FR2741879A1 (fr) * 1995-12-05 1997-06-06 Esteve Labor Dr Derives de fluorophenyl-triazines et pyrimidines, leur preparation et leur application en tant que medicament
US6202491B1 (en) 1997-07-22 2001-03-20 Skf Condition Monitoring, Inc. Digital vibration coupling stud
GB9726987D0 (en) * 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
US6124500A (en) * 1998-03-09 2000-09-26 Rohm And Haas Company Process for synthesizing benzoic acids
GB9812413D0 (en) 1998-06-10 1998-08-05 Glaxo Group Ltd Compound and its use
PL348865A1 (en) * 1998-12-14 2002-06-17 Torrent Pharmaceuticals Ltd An improved process for the preparation of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
IN183150B (cg-RX-API-DMAC10.html) * 1998-12-14 1999-09-25 Torrent Pharmaceuticals Ltd
US20020055177A1 (en) * 1999-03-10 2002-05-09 Glaxo Wellcome Inc. Compound and its use
EP1169060B1 (en) * 1999-04-09 2005-08-31 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
GB9907965D0 (en) * 1999-04-09 1999-06-02 Glaxo Group Ltd Medical use
US6639072B1 (en) 2000-01-03 2003-10-28 Rpg Life Sciences Limited Process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, commonly known as lamotrigine
IL134730A (en) * 2000-02-25 2003-10-31 Chemagis Ltd Process for preparing substituted benzoyl cyanide amidinohydrazones
CN1477976A (zh) 2000-11-30 2004-02-25 �Ʒ� Gaba激动剂与醛糖还原酶抑制剂的组合
PL365927A1 (en) 2000-11-30 2005-01-10 Pfizer Products Inc. Combination of gaba agonists and sorbitol dehydrogenase inhibitors
EP1390355A4 (en) * 2001-02-27 2005-02-23 Teva Pharma NEW CRYSTALLINE FORMS OF LAMOTRIGIN AND METHOD FOR THE PRODUCTION THEREOF
WO2003020273A2 (en) * 2001-09-03 2003-03-13 Newron Pharmaceuticals Spa Pharmaceutical composition comprising gabapentin or an analogue thereof and an $g(a)-aminoamide and its analgesic use
CA2366521C (en) 2001-12-24 2007-03-06 Brantford Chemicals Inc. A new and efficient process for the preparation of lamotrigine and related 3,5-diamino-6-substituted-1,2,4-triazines
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
WO2003090693A2 (en) * 2002-04-23 2003-11-06 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing lamotrigine particles of defined morphology
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
HU225667B1 (en) 2002-09-20 2007-05-29 Richter Gedeon Nyrt Method for producing high-purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
ES2209639B1 (es) 2002-10-31 2005-08-01 Vita Cientifica, S.L. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y obtencion de su intermedio.
EP1603889A1 (en) * 2003-03-17 2005-12-14 Hetero Drugs Limited Novel crystalline forms of lamotrigine
AU2003230193A1 (en) 2003-03-27 2004-10-18 Hetero Drugs Limited Novel crystalline forms of candesartan cilexetil
AU2004237951A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with GABA modulators, anticonvulsants or benzodiazapines
WO2004103340A1 (en) * 2003-05-20 2004-12-02 Ranbaxy Laboratories Limited Water dispersible tablets of lamotrigine
GB2395483A (en) * 2003-07-03 2004-05-26 Jubilant Organosys Ltd Crystalline lamotrigine and its monohydrate
DK1691811T3 (da) 2003-12-11 2014-10-20 Sunovion Pharmaceuticals Inc Kombination af et sedativ og en neurotransmittermodulator og fremgangsmåder til forbedring af søvnkvaliteten og behandling af depression
WO2005082372A1 (en) * 2004-01-29 2005-09-09 Pfizer Products Inc. COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
BRPI0515154A (pt) * 2004-09-10 2008-07-08 Newron Pharm Spa uso de (halobenzilóxi)benzilamino-propanamidas para a fabricação de medicamentos ativos, compostos e composição farmacêutica
EP1937646A1 (en) 2005-09-23 2008-07-02 Janssen Pharmaceutica N.V. Tetrahydro-cyclopentyl pyrazole cannabinoid modulators
JP5162461B2 (ja) * 2005-09-23 2013-03-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヘキサヒドロシクロオクチルピラゾール系カンナビノイドモジュレーター
US8378096B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
US7825151B2 (en) * 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
BRPI0616402A2 (pt) * 2005-09-23 2011-06-21 Janssen Pharmaceutica Nv moduladores de canabinóide de hexaidro-cicloeptapirazol
US20070117858A1 (en) * 2005-11-23 2007-05-24 Mingde Xia Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
WO2007092456A2 (en) * 2006-02-03 2007-08-16 Rolls-Royce Corporation Gas turbine engine fuel system with fuel metering valve
US7795294B2 (en) * 2006-02-14 2010-09-14 Janssen Pharmaceutica N.V. Tetrahydro-2H-indazole pyrazole cannabinoid modulators
US20070254911A1 (en) * 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
WO2007112402A1 (en) * 2006-03-27 2007-10-04 Janssen Pharmaceutica N.V. Tetrahydro-1h-1,2,6-triaza-azulene cannabinoid modulators
WO2007122638A2 (en) * 2006-04-26 2007-11-01 Ratnamani Bio-Chemicals & Pharmaceuticals Pvt. Ltd. An improved process for preparation of lamotrigine intermediates
EP2024345B1 (en) * 2006-05-31 2009-12-16 Calaire Chimie SAS Method for preparing lamotrigine and its intermediate 2,3-dichlorobenzoyl chloride
GB0613836D0 (en) * 2006-07-13 2006-08-23 Univ Greenwich New medical use of triazine derivatives
US20120142919A1 (en) 2006-08-02 2012-06-07 Medichem, S.A. Method for synthesizing lamotrigine
US20100087638A1 (en) * 2006-08-14 2010-04-08 Jean-Paul Roduit Process for the preparation of lamotrigine
KR20090112722A (ko) 2007-01-24 2009-10-28 글락소 그룹 리미티드 3,5-디아미노-6-(2,3-디클로로페닐)-1,2,4-트리아진 또는 ｒ(-)-2,4-디아미노-5-(2,3-디클로로페닐)-6-플루오로메틸 피리미딘 및 ｎｋ1을 포함하는 제약 조성물
US7943653B2 (en) * 2007-08-13 2011-05-17 Janssen Pharmaceutica N.V. Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
US20090076010A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched lamotrigine
US8486927B2 (en) * 2007-11-09 2013-07-16 Thar Pharmaceuticals Crystalline forms of lamotrigine
GB0800741D0 (en) 2008-01-16 2008-02-20 Univ Greenwich Cyclic triazo and diazo sodium channel blockers
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
AU2010248943B2 (en) 2009-05-13 2015-05-21 Nektar Therapeutics Oligomer-containing substituted aromatic triazine compounds
US20100297195A1 (en) 2009-05-20 2010-11-25 Ranbaxy Laboratories Limited Controlled release lamotrigine formulations
GB2471713A (en) * 2009-07-08 2011-01-12 Univ Greenwich 1,2,4-triazine derivatives and their use as sodium channel blockers
GB2471729A (en) 2009-07-08 2011-01-12 Univ Greenwich 1,2,4-triazine derivatives and their use as sodium channel blockers
US20110052686A1 (en) * 2009-09-03 2011-03-03 Ranbaxy Laboratories Limited Modified release lamotrigine tablets
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
WO2013183985A1 (en) 2012-06-05 2013-12-12 Erasmus University Medical Center Rotterdam Method of treating cognitive impairment and compounds for use therein
WO2015092819A2 (en) * 2013-12-21 2015-06-25 Nektar Therapeutics (India) Pvt. Ltd. Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5- amine
US10576086B2 (en) 2015-06-12 2020-03-03 University Of Greenwich Triazine derivatives as interferon-gamma inhibitors
LT3554490T (lt) 2016-12-16 2022-04-25 Idorsia Pharmaceuticals Ltd Farmacinis derinys, apimantis t tipo kalcio kanalo blokatorių
TWI826531B (zh) 2018-09-21 2023-12-21 南韓商愛思開生物製藥股份有限公司 具有㗁二唑之化合物及包含該化合物之醫藥組合物
GB2641294A (en) 2024-05-24 2025-11-26 Novumgen Ltd An orodispersible tablet of Lamotrigine and its process of preparation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB759014A (en) * 1952-02-26 1956-10-10 Wellcome Found Improvements in triazines and their manufacture
AT190941B (de) * 1954-09-22 1957-07-25 Chemie Linz Ag Verfahren zur Herstellung neuer Guanylhydrazone
US2952677A (en) * 1956-10-01 1960-09-13 Ici Ltd Aminoguanadine compounds
BE663481A (cg-RX-API-DMAC10.html) * 1964-05-05
GB1204631A (en) * 1967-10-12 1970-09-09 Shell Int Research Pharmacologically active benzylideneamino guanidines and their use
GB1223492A (en) * 1967-10-13 1971-02-24 American Home Prod Guanidines
US3637688A (en) * 1970-01-09 1972-01-25 American Home Prod 6-(fluoro and trifluoromethyl phenyl)-3 5-diamino - 1 2 4 - triazines and substituted - 6 - phenylalkyl-3,5-diamino-1 2 4-triazines
EP0024351B1 (en) * 1979-08-16 1984-10-31 The Wellcome Foundation Limited Solid pharmaceutical formulation containing substitued phenyl-triazines

Also Published As

Publication number Publication date
JPH0144706B2 (cg-RX-API-DMAC10.html) 1989-09-29
GR68380B (cg-RX-API-DMAC10.html) 1981-12-28
EP0021121B1 (en) 1983-05-11
IT1147087B (it) 1986-11-19
ES8104993A1 (es) 1981-05-16
CS234018B2 (en) 1985-03-14
EP0021121A1 (en) 1981-01-07
CA1112643A (en) 1981-11-17
BG60427B2 (bg) 1995-03-31
ZW12980A1 (en) 1982-01-06
US4602017A (en) 1986-07-22
ZA803250B (en) 1982-01-27
US4486354A (en) 1984-12-04
EP0059987B1 (en) 1985-08-14
NZ193890A (en) 1984-07-06
JPS6133163A (ja) 1986-02-17
ATA289680A (de) 1982-07-15
DD151309A5 (de) 1981-10-14
UA5576A1 (uk) 1994-12-28
PL224633A1 (cg-RX-API-DMAC10.html) 1981-02-13
IE801126L (en) 1980-12-01
AU566870B2 (en) 1987-11-05
IT8048848A0 (it) 1980-05-30
ES491998A0 (es) 1981-05-16
AT370097B (de) 1983-02-25
DK233880A (da) 1980-12-02
FI67844C (fi) 1985-06-10
YU145680A (en) 1983-02-28
EP0059987A1 (en) 1982-09-15
FI801758A7 (fi) 1980-12-02
AR227521A1 (es) 1982-11-15
HU182086B (en) 1983-12-28
IL60201A (en) 1984-05-31
IE49823B1 (en) 1985-12-25
SU1055331A3 (ru) 1983-11-15
PL124029B1 (en) 1982-12-31
JPH0144179B2 (cg-RX-API-DMAC10.html) 1989-09-26
IL60201A0 (en) 1980-07-31
MX9202962A (es) 1992-07-01
DK153787C (da) 1989-01-16
CZ384891A3 (en) 1993-10-13
DK153787B (da) 1988-09-05
MY8500062A (en) 1985-12-31
JPS5625169A (en) 1981-03-10
NL950007I1 (nl) 1995-06-16
NL950007I2 (nl) 1997-02-03
FI67844B (fi) 1985-02-28
AU5890680A (en) 1980-12-04
GEP19960470B (en) 1996-08-29

Similar Documents

Publication Publication Date Title
AU530999B2 (en) Substituted amino triazines and their use in treatment of cns disorders
ZA804180B (en) Medicaments for the treatment of disorders in lipometabolism and their use
DE3363472D1 (en) Process for the preparation of n-substituted n-cyano-amides and their use
EP0097960A3 (en) Bis-crown-ether derivatives and their use
GR80874B (en) Ophthalmic use of norfloxacin and related antibiotics
GR80171B (en) N-(2-nitrophenyl)-4-aminopyrimidine derivatives process for the preparation thereof and use
ZM6780A1 (en) Preparations for the treatment of theileriosis and their use
IL64047A0 (en) Spiro-quaternary ammonium halides and their use in the preparation of n-(2-pyrimidinyl)piperazinyl-alkylazaspiroalkanediones
JPS5653655A (en) Amino acid derivatives and their manufacture
EP0069232A3 (en) Purified antineoplaston fractions and methods of treating neoplastic disease
DE3164345D1 (en) Novel triamine derivatives and their use
GB8303349D0 (en) Hair treatment process and composition
JPS5620570A (en) Manufacture of thienamycin and intermediate thereof
AU5090979A (en) Triazinones and their use in the production of imidazotria- zinones
AU530790B2 (en) Triazinones and their use in treating gastrointestinal disorders
GB2071091B (en) Acyl-derivatives of carnitine and the therapeutic use thereof
GB2203645B (en) Improvements in the treatment of hair
DE3171366D1 (en) The dressing and forming of grinding wheels
GB2103216B (en) Process for the preparation of n-substituted methacrylamides and acrylamides
DE3362345D1 (en) Mixtures of specific 1,2-cycloaliphatic diepoxydes, and use thereof
PH17355A (en) Ergots and their use in treating minimal brain dysfunction
GB2049691B (en) Process for the preparation of 6-(substituted amino)-3-pyridazinylhydrazines and their salts
GB2086903B (en) Novel quinazolinones and their use in the preparation of triazoloquinazolinone derivatives
AU2153092A (en) Spirofurane derivatives and their use in the treatment of neurological disorders
GB2040681B (en) Use in the treatment of hypertension and intestinal disorders of certain n - aryl - n - (2-imidazolidinylidene)-urea